Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

06-06-2022 | ASCO 2022 | Conference coverage | Video

ATLANTIS rules out cabozantinib as a maintenance option for mUC

Robert Jones explains why the ATLANTIS trial findings do not support the use of single-agent cabozantinib for the maintenance treatment of metastatic urothelial carcinoma, and what they mean for the role of VEGFR-targeted therapies in this tumor type (3:23).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

30-05-2020 | ASCO 2020 | News

Maintenance avelumab ‘new standard of care’ for advanced urothelial cancer

20-02-2022 | ASCO GU 2022 | Conference coverage | News

Maintenance rucaparib feasible for platinum-responsive mUC with DRD biomarkers

19-02-2022 | ASCO GU 2022 | Conference coverage | News

Maintenance niraparib fails to improve advanced urothelial cancer PFS

28-01-2022 | Immunotherapy | Video

Recent developments in immunotherapy for patients with mUC (ESMO IO)
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits